Skip to content

Evaluation of the efficacy and safety of dexmedetomidine nasal spray inBronchoscopy Examination

Application of Dexmedetomidine Nasal Spray in Bronchoscopy Examination

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600125256
Enrollment
Unknown
Registered
2026-05-24
Start date
2026-05-30
Completion date
Unknown
Last updated
2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Normal Saline Group:Normal saline spray was evenly administered into both nostrils of the patients 30 minutes before the operation.
Dexmedetomidine Nasal Spray Group:Dexmedetomidine nasal spray was evenly administered into both nostrils of the patients 30 minutes before the operation.

Sponsors

Quzhou People Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age: 18 to 70 years old; 2. American Society of Anesthesiologists (ASA) Physical Status Classification I to III; 3. scheduled for flexible bronchoscopy; 4. Preoperative liver and kidney function test results within the normal reference range, with no definite surgical or anesthetic contraindications; 5. No cardiovascular diseases such as significant ST-T segment changes on electrocardiogram or severe arrhythmia; 6. Patients and their family members have been informed of the study and provided informed consent to participate.

Exclusion criteria

Exclusion criteria: 1. Patients with nasal administration contraindications such as nasal anatomical abnormalities or a history of epistaxis, or those who refuse to receive nasal administration; 2. Body Mass Index (BMI) 30 kg/m²; 3. Resting heart rate Grade III; 6. Intraoperative occurrence of active massive hemorrhage (blood loss > 100 mL) or malignant arrhythmia requiring emergency treatment; 7. Patients currently participating in other clinical trials; those deemed unsuitable for the clinical trial by researchers due to other reasons.

Design outcomes

Primary

MeasureTime frame
Preoperative Anxiety Score;

Secondary

MeasureTime frame
Ramsay Sedation Scale;The occurrence of anesthesia-related adverse reactions;Time to Discharge from Post-Anesthesia Care Unit (PACU) and Discharge Score (Aldrete Score);Oxygen saturation, blood pressure and heart rate change;

Countries

China

Contacts

Public ContactFang Xiangyu

Quzhou People Hospital

fangxy999@foxmail.com+86 570 305 1425

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 30, 2026